Cognito Therapeutics

Summary

Cognito Therapeutics closed an oversubscribed $105 million Series C financing round. The funding is expected to support a pivotal data readout, regulatory submission, and commercial launch preparation ahead of an anticipated 2027 market entry for Spectris, the company's investigational at-home therapy for Alzheimer's disease.